| 13.8512 0.001 (0.01%) | 10-15 12:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.94 | 1-year : | 17.69 |
| Resists | First : | 14.5 | Second : | 15.14 |
| Pivot price | 14.22  |
|||
| Supports | First : | 13.47 | Second : | 11.2 |
| MAs | MA(5) : | 14.03 |
MA(20) : | 14.19 |
| MA(100) : | 12.27  |
MA(250) : | 10.47 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 18.5 |
D(3) : | 22.8 |
| RSI | RSI(14): 48.2 |
|||
| 52-week | High : | 15.14 | Low : | 7.9 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TBPH ] has closed above bottom band by 22.4%. Bollinger Bands are 29.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.31 - 14.4 | 14.4 - 14.46 |
| Low: | 13.62 - 13.73 | 13.73 - 13.81 |
| Close: | 13.7 - 13.87 | 13.87 - 13.99 |
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; Nezulcitinib, a lung-selective, nebulized JAK inhibitor, which is in Phase II clinical development for the potential treatment of hospitalized patients with acute lung injury caused by COVID-19; Inhaled ALK5i, a potential inhaled anti-fibrotic agent that is in Phase I for the treatment of idiopathic pulmonary fibrosis; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD and asthma; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. Theravance Biopharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.
Tue, 14 Oct 2025
Theravance Biopharma Presents YUPELRI: Fewer COPD Exacerbations | TBPH Stock News - Stock Titan
Tue, 14 Oct 2025
Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting - PR Newswire
Sun, 21 Sep 2025
Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update - MarketBeat
Tue, 02 Sep 2025
Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PR Newswire
Fri, 29 Aug 2025
Theravance Biopharma, Inc.'s (NASDAQ:TBPH) 27% Share Price Surge Not Quite Adding Up - simplywall.st
Thu, 14 Aug 2025
Theravance Biopharma (NASDAQ:TBPH) shareholder returns have been respectable, earning 51% in 1 year - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 92.9 (%) |
| Shares Short | 4,950 (K) |
| Shares Short P.Month | 4,460 (K) |
| EPS | 0.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.46 |
| Profit Margin | 16.8 % |
| Operating Margin | -10.4 % |
| Return on Assets (ttm) | -5.7 % |
| Return on Equity (ttm) | 6.2 % |
| Qtrly Rev. Growth | 83.6 % |
| Gross Profit (p.s.) | 0.72 |
| Sales Per Share | 1.53 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 245 (M) |
| Levered Free Cash Flow | 23 (M) |
| PE Ratio | 57.99 |
| PEG Ratio | 0 |
| Price to Book value | 3.11 |
| Price to Sales | 9.07 |
| Price to Cash Flow | 2.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|